Skip To Main Content
d'Arbitrage de Paris on Muck Rack

d'Arbitrage de Paris

As seen in: Sparda-Bank web.Börsenforum
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with d'Arbitrage

Contact d'Arbitrage, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PSD Bank Rhein-Ruhr eG

|
By Donald J. Bergstrom, d'Arbitrage de Paris
| Sparda-Bank web.Börsenforum
* Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented * End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025 * Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 * eti-cel (UCART20x22): Phase 1 study in r/r NHL ongoing with readout...
Open in Who Shared View Duplicates (85) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By d'Arbitrage de Paris
| Sparda-Bank web.Börsenforum
* Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) * ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) * Median OS of 14.8 months in patients who achieved MRD-negative CR/CRi * First interim analysis for the BALLI-01 trial expected in Q4 2026 Eti-cel in r/r NHL (NATHALI-01) * * ORR of 86% and 57% CR rate (n=7) *...
Open in Who Shared View Duplicates (204) Issue with article?
See all 2 articles